FDA panel endorses 2 RSV vaccines for older adults, but flag at potential increased risk of Guillain-Barre

Pfizer vaccine:

In close vote, FDA advisers recommend Pfizer RSV vaccine for those 60 and older – CIDRAP

FDA advisors recommend first-ever RSV vaccine from Pfizer, despite possible Guillain-Barre risks – CNBC

GSK’s vaccine:

FDA panel recommends GSK’s RSV vaccine for ages 60 and up – CIDRAP

FDA advisors recommend GSK’s RSV vaccine for older adults, but flag potential safety risks – CNBC

See also: Rare neurological condition is ‘important potential risk’ of Pfizer’s RSV vaccine, FDA says – CNN